The thrombosed prosthetic valve**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. Current recommendations based on evidence from the literature* by Alpert, Joseph S
EDITORIAL COMMENT
The Thrombosed Prosthetic Valve
Current Recommendations Based on
Evidence From the Literature*
Joseph S. Alpert, MD, FACC
Tucson, Arizona
The four most dreaded complications following mechanical
prosthetic valve replacement are dehiscence/disruption/
dysfunction, infection, embolism, and thrombosis (mne-
monic). Thrombosis of a mechanical prosthetic valve (TPV)
is a particularly pernicious complication because it is often
associated with embolism and/or life-threatening deteriora-
tion in the patient’s clinical status (1). In this issue of the
Journal, Roudaut et al. (2) from Bordeaux review their
institution’s 23-year experience with thrombosed mechani-
cal prosthetic valves. The catchment area for their hospital
includes three million inhabitants. They observed 127
instances of TPV in 110 patients during their study. The
overwhelming majority of individuals with TPV were man-
aged medically with thrombolytic therapy followed by
antithrombotic therapy. The results were encouraging and
not dissimilar from previously reported large series (3–9).
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Most patients with TPV in this series, as in others,
presented with embolism, dyspnea, or other symptoms of
heart failure including pulmonary edema with or without
hypotension. Patients with massive valve thrombosis more
often presented with severe symptoms. Mitral prosthetic
valves were affected more commonly than aortic valves; the
most frequent underlying reason for TPV was inadequate
anticoagulant therapy with warfarin. The diagnosis of TPV
was confirmed by either transthoracic or transesophageal
echocardiographic study. During medical therapy, serial
echocardiographic studies were employed to document the
success or failure of thrombolytic/antithrombotic therapy.
Thrombolytic therapy was not administered to patients
with large left atrial thrombi in addition to TPV (2). In
these individuals, it was felt that thrombolytic therapy
would be associated with an inordinately high risk for
systemic embolism secondary to dissolution of the left atrial
thrombus. Tissue plasminogen activator (tPA) and strep-
tokinase (SK) were more effective than urokinase in dissolv-
ing prosthetic valve thrombi. This is a particularly fortunate
finding because urokinase is currently unavailable in the
U.S. Repeated courses of intravenous thrombolytic therapy
were necessary for complete resolution of prosthetic valve
thrombosis in nearly one-third of the patients in this series
(2). This is an important finding because U.S. clinicians are
more likely to employ surgical intervention in patients with
TPV, particularly if the initial infusion of thrombolytic
therapy has not resulted in complete clearing of valve-
associated thrombus.
Valve replacement was employed in only 23% of the
patients in the current series (2). In each of these patients,
surgical intervention followed unsuccessful or partially suc-
cessful intravenous thrombolytic therapy. Medical therapy
resulted in total dissolution of prosthetic valve-associated
thrombus in 71% of patients and partial dissolution of
thrombus in an additional 17%. Medical therapy failed in
12% of individuals with TPV. Thrombolytic therapy was
more commonly successful in patients with aortic prosthetic
valves (80%) as compared with mitral prostheses (65%).
Thrombolytic therapy was associated with severe hemor-
rhagic complications in 5% of patients and with systemic
embolism in 15%. However, systemic embolism resulted in
cerebral infarction in only 7% of treated patients (n  8),
although all but one of these individuals died. Other
systemic embolic complications included transient ischemic
attacks and peripheral embolism that were successfully
managed with further medical therapy. Mortality in this
series was only 12%. Recurrent valve thrombosis necessitat-
ing repeat thrombolytic therapy and/or surgery was observed
in nearly 20% of patients treated (2).
The authors argue that medical therapy can and should be
employed for most patients with TPVs on the basis of the
results observed in their institution over a 23-year period.
Moreover, they suggest that thrombosed right-sided pros-
thetic valves should almost always be treated medically,
whereas left-sided valves should undergo surgical interven-
tion if the patient’s symptoms are mild-to-moderate and
general physical condition is good. They support these
recommendations with their own data as well as with
citations from earlier collected series and meta-analyses that
report an 8% to 20% mortality when surgical intervention is
employed as the primary modality for patients with an
“urgent” need for therapy (2–10). These same published
series report surgical mortalities in excess of 35% when
patients are deemed to be “critically ill.” Mortality is lower
and apparently comparable with both medical and surgical
therapy when patients present in New York Heart Associ-
ation (NYHA) clinical class I or II.
In 1997, a consensus conference of clinicians and inves-
tigators working in this area proposed that surgical inter-
vention should be the preferred treatment modality for most
patients with TPV (10). Thrombolytic therapy was recom-
mended only for individuals who were poor surgical candi-
dates or critically ill, that is, in NYHA clinical classes III or
IV. These authors were concerned by the high rate of
systemic embolism associated with thrombolytic therapy
(10). However, the series of Roudaut et al. (2) in this issue
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of the Journal demonstrates that embolic events following
medical therapy are more often of a benign nature than
previously thought. Thus, the present series of patients
should cause us to pause and reconsider the earlier recom-
mendations of Lengyel et al. (10).
Fortunately, thrombosis of a prosthetic valve is not a
common occurrence. However, this makes it very unlikely
that a study will ever be done randomly comparing medical
to surgical therapy. Recommendations for the management
of these patients, therefore, will need to be based on series
such as the one presented in this issue of the Journal,
together with previously reported clinical experience and
consensus conference recommendations from the medical
literature. The recently published American College of
Cardiology/American Heart Association (ACC/AHA)
guidelines for patients with valvular heart disease mentioned
TPV briefly, but suggested no firm recommendations for
the management of these individuals (11). In an effort to
further discussion in this area, I have listed a series of
tentative recommendations for managing these seriously ill
patients. The recommendations are couched in the style of
ACC/AHA guideline documents. However, these are my
own personal recommendations. They should not be con-
strued in any way as reflecting the opinion of the ACC/
AHA Task Force on Practice Guidelines or any of its
writing committees. This caveat is particularly important
because I am currently a member of this task force.
Therefore, it would be distressing to me as well as to the
committee if the recommendations included in this editorial
were misconstrued as having any official imprimatur from
the ACC/AHA Task Force on Practice Guidelines.
In conclusion, my proposed recommendations for pa-
tients who present with a thrombosed prosthetic valve are
listed here. These recommendations are based on my own
personal reading of the medical literature, including the
excellent article by Roudaut et al. (2) from this issue of
the Journal:
1. All patients with suspected TPVs should undergo echo-
cardiographic study. If adequate visualization of the
prosthetic valve is not obtained by a transthoracic study,
then a transesophageal echocardiographic study should
be undertaken (level of evidence I).
2. Patients with right-sided TPVs should be treated with
intravenous rtPA (100 mg administered as 10 mg im-
mediate intravenous bolus followed by 90 mg infused
over 90 min) or SK (500,000 IU over 20 min followed by
1.5 million IU infused over 10 h). Reduced doses should
be employed in children and very small adults (level of
evidence IIa).
3. Patients who are critically ill on presentation with TPV
(pulmonary edema, hypotension, NYHA class III/IV
symptoms) should receive immediate intravenous
thrombolytic therapy as outlined earlier following appro-
priate echocardiographic confirmation of TPV (level of
evidence IIa).
a. Serial echocardiographic studies should be performed
in these individuals, and repeated infusions of throm-
bolytic therapy should be administered if complete
resolution of prosthetic valve thrombus is not
achieved (level of evidence IIa).
b. Concomitant intravenous unfractionated heparin
should be administered along with thrombolytic ther-
apy to achieve an activated partial thromboplastin
time that is 1.5 to 2.0 times control (level of evidence
IIb).
c. Cardiac surgical consultation should be sought ur-
gently. Valve replacement should be seriously consid-
ered if repeated infusions of thrombolytic therapy fail
to adequately dissolve the thrombus on the prosthetic
valve (level of evidence IIa).
4. Patients with TPV who are clinically stable, that is, in
NYHA clinical class I or II, may be managed medically
with thrombolytic/antithrombotic therapy or surgically
with valve replacement depending on physician/patient
preference (level of evidence IIa).
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